Hunan Er-Kang Pharmaceutical Co., Ltd

XSEC:300267 Stock Report

Market Cap: CN¥6.6b

Hunan Er-Kang Pharmaceutical Balance Sheet Health

Financial Health criteria checks 4/6

Hunan Er-Kang Pharmaceutical has a total shareholder equity of CN¥4.7B and total debt of CN¥399.4M, which brings its debt-to-equity ratio to 8.5%. Its total assets and total liabilities are CN¥5.4B and CN¥695.7M respectively.

Key information

8.5%

Debt to equity ratio

CN¥399.39m

Debt

Interest coverage ration/a
CashCN¥768.37m
EquityCN¥4.70b
Total liabilitiesCN¥695.74m
Total assetsCN¥5.39b

Recent financial health updates

No updates

Recent updates

Financial Position Analysis

Short Term Liabilities: 300267's short term assets (CN¥1.7B) exceed its short term liabilities (CN¥626.9M).

Long Term Liabilities: 300267's short term assets (CN¥1.7B) exceed its long term liabilities (CN¥68.8M).


Debt to Equity History and Analysis

Debt Level: 300267 has more cash than its total debt.

Reducing Debt: 300267's debt to equity ratio has increased from 0% to 8.5% over the past 5 years.

Debt Coverage: 300267's debt is well covered by operating cash flow (61.8%).

Interest Coverage: Insufficient data to determine if 300267's interest payments on its debt are well covered by EBIT.


Balance Sheet


Discover healthy companies